Health & Medical Archives | Page 7 of 245 | Be Korea-savvy

Archive by category Health & Medical

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Presentations highlight key preclinical data that support investigational new drug application (IND) submissions for ZW220 in 1H and ZW251 in 2H in 2025 VANCOUVER, British Columbia, Oct. 25, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for [...]

Philips and Medtronic advocacy partnership aims to help accelerate access to life-saving treatments

Philips and Medtronic advocacy partnership aims to help accelerate access to life-saving treatments

October 24, 2024 Both companies also join the newly established World Stroke Organization Advocacy Coalition Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke care is crucial to saving lives and reducing long-term [...]

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are up to 175,000 cases of recurrent C. diff. each [...]

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024 SELARSDI’s U.S. launch for all indications is [...]

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW171 in treatment of ovarian cancer, non-small cell lung cancer (NSCLC), and other mesothelin (MSLN) expressing cancers VANCOUVER, British Columbia, Oct. 21, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to [...]

AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024

AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024

Research Triangle Park, N.C., Oct. 17, 2024 (Korea Bizwire) – Two oral presentations and nine poster presentations will highlight exciting progress in AskBio’s clinical and pre-clinical pipeline and advancements in the company’s manufacturing technologies Alongside recent clinical program milestones, presentations demonstrate AskBio’s commitment to advancing end-to-end capabilities and goal of delivering breakthrough therapies Asklepios BioPharmaceutical, [...]

Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate

Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate

– BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development – – Phase 1/2a study will evaluate BPT567 in patients with locally advanced/unresectable or metastatic solid tumors – BASEL, Switzerland and SAN DIEGO, Oct. 17, 2024 (Korea Bizwire) – Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies [...]

Fortrea Releases Inaugural Corporate Social Responsibility Report

Fortrea Releases Inaugural Corporate Social Responsibility Report

DURHAM, N.C., Oct. 17, 2024 (Korea Bizwire) – Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the release of the company’s inaugural Corporate Social Responsibility report, “Fortrea for Better.” Available for download on Fortrea.com, the report describes Fortrea’s environmental, social and governance (ESG) activities, reported across four distinct sections: Fortrea for Life: Responsible Environmental Practices [...]

Capsa Healthcare Announces New Interface to EMIS ProScript Connect for RoboWall Prescription Pickup Efficiency

Capsa Healthcare Announces New Interface to EMIS ProScript Connect for RoboWall Prescription Pickup Efficiency

A Media Snippet accompanying this announcement is available by clicking on this link. COLUMBUS, Ohio, Oct. 17, 2024 (Korea Bizwire) – Capsa Healthcare, a leading provider of central fill and medication management solutions, today announced the new, seamless integration of its RoboWall prescription retrieval kiosk system with EMIS ProScript Connect,  a leading United Kingdom pharmacy patient medication [...]

Astec acquires AI fertility product Life Whisperer

Astec acquires AI fertility product Life Whisperer

FUKUOKA, Japan, Oct. 17, 2024 (Korea Bizwire) – Astec, a global manufacturer of medical equipment for assisted reproduction, has acquired Life Whisperer, a non-invasive and rapid embryo and egg (oocyte) assessment tool designed to improve pregnancy outcomes for IVF patients. Life Whisperer comprises three AI algorithms. Life Whisperer Viability assesses images of embryos to determine [...]